Welcome to our dedicated page for TELEFLEX SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
TELEFLEX INC executive Daniel V. Logue, CVP, General Counsel & Secretary, acquired 443 shares of common stock on a grant/award basis at no cost. The shares relate to performance stock units whose conditions were determined satisfied on February 23, 2026 and remain subject to vesting on February 28, 2026. Following this award, he holds 15,414.888 shares directly and 300.876 shares indirectly through a 401(k) trustee.
Winters James reported acquisition or exercise transactions in this Form 4 filing.
Teleflex Inc. corporate vice president James Winters reported an equity award of 354 shares of common stock. The award reflects performance stock units whose performance conditions were determined to be satisfied on February 23, 2026 and that are payable solely in shares.
These units remain subject to vesting on February 28, 2026, meaning Winters does not fully own them until that date. After this award, his directly held common stock reported in this filing totals 5,661 shares.
Deren John reported acquisition or exercise transactions in this Form 4 filing.
Teleflex Executive Vice President & CFO John Deren reported an equity award of 161 shares of common stock on February 23, 2026, at $0.00 per share, from performance stock units whose conditions were satisfied. These units remain subject to vesting on February 28, 2026. After the award, Deren directly holds 4,749 common shares, with an additional 4.308 shares held indirectly through a 401(k) trustee.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report a passive ownership stake in Teleflex Inc. They beneficially own 1,923,208 shares of Teleflex common stock, representing 4.35% of the class as of 12/31/2025.
The firms hold shared voting and shared dispositive power over all reported shares, with no sole voting or dispositive power. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Teleflex.
Morgan Stanley and Atlanta Capital have reduced their holdings in Teleflex Inc. common stock to below 5% each. As of the report date, Morgan Stanley reports beneficial ownership of 2,162,407 shares, representing 4.9% of the class, while Atlanta Capital reports 1,911,845 shares, or 4.3%.
Both firms report only shared voting and dispositive power over these shares and state that the securities were acquired and are held in the ordinary course of business, not to change or influence control of Teleflex.
Teleflex Incorporated has finalized the transition of former President and CEO Liam J. Kelly. His departure from the CEO role was effective at the end of the day on January 7, 2026, and he resigned from the Board on January 23, 2026, when he signed a separation agreement and release.
The separation agreement provides Mr. Kelly with the benefits applicable to a termination without cause under his March 31, 2017 severance agreement, contingent on his release of claims. His outstanding equity awards receive age and service-based vesting treatment as provided in existing equity award agreements.
Mr. Kelly will remain an employee through March 31, 2026 in a transition role. During this period he will continue to receive base salary, remain eligible for his existing health, welfare and 401(k) benefits, be paid any 2025 Annual Incentive Plan bonus that becomes payable during the transition, and vest in equity awards scheduled to vest in that timeframe, but will receive no new equity grants. Existing restrictive covenants under his severance agreement remain in effect.
Teleflex Inc. (TFX) reported that Interim President and CEO Stuart A. Randle received an equity award in the form of restricted stock units. On January 13, 2026, he was granted 12,325 shares of common stock at a price of $0 per share, increasing his directly held beneficial ownership to 19,872 shares. The award was granted under the Teleflex Incorporated 2023 Stock Incentive Plan in connection with his appointment as Interim President and CEO.
The restricted stock units vest on the earlier of the date a permanent Chief Executive Officer begins employment with Teleflex or January 13, 2027, provided Randle continues to serve the company through that vesting date. This filing reflects an equity-based compensation grant rather than an open-market purchase or sale.
Teleflex Incorporated disclosed a major leadership change and shared that it has issued estimated preliminary financial information for the full year ended December 31, 2025 via a separate press release. The filing reports that Liam J. Kelly has departed his roles as President and Chief Executive Officer, effective at the end of the day on January 7, 2026.
Effective January 8, 2026, long‑time director Stuart A. Randle has been appointed Interim President and Chief Executive Officer, while continuing to serve on the Board. The Board also named Stephen K. Klasko, M.D., as independent Chair and engaged search firm Spencer Stuart to help identify a permanent CEO.
Under a letter agreement, Mr. Randle will receive a stipend of $140,000 per month and a restricted stock grant with a grant date fair value of $1.5 million, vesting on the earlier of the permanent CEO’s start date or the first anniversary of grant, subject to continued service. Mr. Kelly’s severance and equity treatment will follow his existing 2017 severance agreement, contingent on his executing a release of claims.
Teleflex Incorporated announced two major divestitures and a large capital return plan. The company agreed to sell its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg for $1,500,000,000 in cash, subject to customary adjustments, with a potential $90,000,000 termination fee payable to Teleflex if the buyer fails to close under certain conditions. It also agreed to sell its acute care and interventional urology segments to Intersurgical Limited for $530,000,000 in cash, also subject to customary adjustments. Both transactions require regulatory approvals and are expected to close in the second half of 2026, with outside dates extending into 2027 for the second deal. Teleflex primarily intends to use net proceeds to return capital to shareholders and reduce debt, and its board authorized a share repurchase program of up to $1 billion, which will be mainly funded from these transactions.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G (Amendment No. 5) disclosing a passive stake in Teleflex Inc. (TFX). The firm reported beneficial ownership of 4,569,043 shares, representing 10.3% of the common stock, as of 09/30/2025.
T. Rowe Price reported sole voting power over 4,556,673 shares and sole dispositive power over 4,569,043 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The reporting person is classified as an investment adviser (IA).